cholinergic transmission

Every compound in the sci-wiki that affects cholinergic transmission; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 2 reference

←cholinergic transmission2/2

Nootropic

Besipirdine

Besipirdine was Hoechst-Roussel's attempt to broaden the cholinergic-hypothesis playbook for Alzheimer's disease by hitting two neurotransmitter systems at once, enhancing both cholinergic and noradrenergic transmission rather than acetylcholine alone, on the theory that a dual mechanism might outperform pure cholinesterase inhibitors. In a 275-patient trial, patients on besipirdine held steady on cognitive testing over three months while the placebo group declined, a genuinely encouraging signal for a still-experimental Alzheimer's drug in the mid-1990s. That promise collapsed in Phase III, where a subset of patients developed serious cardiovascular side effects, forcing Hoechst-Roussel to abandon the program; the company had also explored besipirdine for other indications, including multiple sclerosis-related walking impairment, but none of it reached market.

reference

Nootropic

Velnacrine

Velnacrine is the main liver metabolite of tacrine, and Hoechst-Roussel developed it under the name Mentane hoping that using the metabolite directly, rather than relying on the body to convert tacrine into it, might dodge tacrine's notorious liver-toxicity problem. It did not; clinical trials found the same pattern of asymptomatic but concerning liver-enzyme elevations that had plagued tacrine, and researchers built a statistical risk model (called PROPP) just to try to predict which Alzheimer's patients would develop hepatotoxicity before exposing them to the drug. Hoechst-Roussel ultimately dropped velnacrine after regulators would not approve it on the safety data submitted, a case of a cleaner metabolite turning out to share its parent drug's core problem.

reference